Biotechnology company Imugene (ASX:IMU) said the first patient was dosed in the intratumoral combination group of phase 1 clinical trial on its oncolytic virotherapy candidate, CD19, according to a Monday filing with the Australian bourse.

The study is part of the company's Oasis trial, which aims to evaluate the safety and efficacy of CD19 in patients with advanced or metastatic solid tumors, the filing said. It will explore the direct administration of CD19 into the tumor, as well as intravenous infusion.

The trial is being conducted at seven US sites, with the potential to open a total of 10 sites to recruit up to 40 patients, according to the filing.